Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
309M
-
Number of holders
-
262
-
Total 13F shares, excl. options
-
276M
-
Shares change
-
+1.15M
-
Total reported value, excl. options
-
$6.36B
-
Value change
-
+$51M
-
Put/Call ratio
-
1.43
-
Number of buys
-
125
-
Number of sells
-
-119
-
Price
-
$23.09
Significant Holders of AMICUS THERAPEUTICS, INC. - Common Stock, par value $0.01 per share (FOLD) as of Q4 2020
324 filings reported holding FOLD - AMICUS THERAPEUTICS, INC. - Common Stock, par value $0.01 per share as of Q4 2020.
AMICUS THERAPEUTICS, INC. - Common Stock, par value $0.01 per share (FOLD) has 262 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 276M shares
of 309M outstanding shares and own 89.2% of the company stock.
Largest 10 shareholders include PERCEPTIVE ADVISORS LLC (25.1M shares), VANGUARD GROUP INC (23.8M shares), BlackRock Inc. (21.9M shares), Redmile Group, LLC (20.6M shares), MORGAN STANLEY (12.7M shares), JANUS HENDERSON GROUP PLC (11.2M shares), WELLINGTON MANAGEMENT GROUP LLP (10.1M shares), Avoro Capital Advisors LLC (9M shares), JPMORGAN CHASE & CO (8.46M shares), and STATE STREET CORP (7.91M shares).
This table shows the top 262 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.